Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

ted on MX-2401 have demonstrated very favorable activity with low toxicity, a long half-life, and other positive pharmacological and competitive features (with efficacy in multiple animal models, including pneumonia). Good Laboratory Practices ("GLP") compliant non-clinical studies were initiated in April 2007. Activities in the program are currently focused on manufacturing process development and advancing the program into the clinic in late 2009.

SB 9000 (dinucleotide; treatment of chronic hepatitis B virus infections): This preclinical program was out-licensed to Spring Bank Technologies and is supported in part with NIH funding. Spring Bank has made significant progress and plans to advance the program into the clinic in 2009. We have a convertible preferred share ownership position in Spring Bank.

MX-4565 (small molecule; treatment of neurodegenerative diseases): In June 2007 we were awarded a grant from the Michael J. Fox Foundation to fund research in our MX-4565 program. Studies funded by the grant are ongoing.

Other Matters: We provided notice to the University of Florida Research Foundation Inc. (UFRFI) of the termination of the license agreement between the Company and UFRFI. The license agreement relates primarily to the Company's MX-4509 program that was written off in the year ended April 30, 2007.

FINANCIAL RESULTS

For the three months ended January 31, 2008 ("Q3/08"), MIGENIX incurred a loss of $3.4 million (Q3/07: $6.7 million) or $0.04 (Q3/07: $0.08) per common share, and for the nine months ended January 31, 2008 ("YTD Fiscal 2008") the loss is $9.5 million ($0.10 per common share) compared to a loss of $12.9 million ($0.16 per common share) for the nine months ended January 31, 2007 ("YTD Fiscal 2007"). The YTD Fiscal 2008 loss includes $2.5 million in non-cash expenses (YTD Fiscal 2007: $5.5 million). The $3.3 million decrease in the Q3/08 loss compared to the Q3/07 loss is principally attributable to a $2.8 m
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Riviera Beach, Florida based ... creation of the Sancilio Scientific Advisory Board (SSAB). ... philosophy of looking to nature for pharmaceutical advancements, ... are based on sound scientific data, analyses, expertise ... provides a vehicle for SCI to receive peer ...
(Date:8/27/2014)... According to the 2013 Raw Material and ... and feel of markets for raw materials and ingredient ... push for more branded, science-backed products.” , Natural products ... growth in the last decade as consumers increasingly demand ... to fit a more ‘wellness’ lifestyle approach. Due ...
(Date:8/27/2014)... Ohio (PRWEB) August 27, 2014 ... from Cleveland's University School participated in ... Case Western Reserve University’s School of Medicine . ... students with an unparalleled professional experience in the ... School of Medicine faculty and students for both ...
(Date:8/26/2014)... and Bellingham, WA (PRWEB) August 26, 2014 ... engineering, visions for next-generation wearable technology, and inspiration ... numerous highlights at this year’s brighter, busier ... Diego, California, Convention Center. More than 4,400 international ... attended conferences, courses, an exhibition, and industry sessions ...
Breaking Biology Technology:New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4
... Calif., Oct. 26 iDiverse announced that it has ... number of lethal stresses normally encountered in the bioproduction ... the yeast to generate significantly more ethanol. ... proof-of-concept technology and are rapidly developing a 2nd generation ...
... a microwave oven, the fundamental nanotechnology process of ... use to make the ubiquitous semi-conductor chips. By ... Nanotechnology (NINT) and the University of Alberta have ... molecular self-assembly process used to assemble block copolymers, ...
... BSI Announces Global Launch of Clinical Strategy Review for CE Marking -- RESTON, Virginia, October 25, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Biology Technology:iDiverse Develops Stress Resistant Yeast for Producing Fuel Ethanol 2BSI Announces Global Launch of Clinical Strategy Review for CE Marking 2BSI Announces Global Launch of Clinical Strategy Review for CE Marking 3BSI Announces Global Launch of Clinical Strategy Review for CE Marking 4BSI Announces Global Launch of Clinical Strategy Review for CE Marking 5BSI Announces Global Launch of Clinical Strategy Review for CE Marking 6BSI Announces Global Launch of Clinical Strategy Review for CE Marking 7BSI Announces Global Launch of Clinical Strategy Review for CE Marking 8BSI Announces Global Launch of Clinical Strategy Review for CE Marking 9
(Date:8/27/2014)... of studies have shown that excessive iron ... Parkinson,s disease. Previous studies from Chunyan Guo ... China have shown that baicalin prevented iron ... metal transporter 1 expression, and increased ferroportin ... rotenone-induced Parkinson,s disease rats. However, the relationship ...
(Date:8/27/2014)... has shown that piglets can be weaned later with ... outcome of the study at the University,s Roseworthy campus, ... is an important finding for pig producers. It allows ... production. , "Sows don,t usually start their oestrous cycles ... piglets have been weaned," says Ms Alice Weaver, PhD ...
(Date:8/27/2014)... is a dreaded bacterium that can be found ... few weeks, 28 persons in Denmark have been infected ... supermarkets. 13 have died. , The bacterium is notoriously ... ability to adapt to changes in its surroundings, says ... with colleagues from the Department of Biochemistry and Molecular ...
Breaking Biology News(10 mins):Piglet weaning age no bar to litter frequency 2Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3
... University School of Medicine (BUSM) report that physicians who use ... on patients with an abnormal Pap test could increase the ... achieve resolution in less time than using traditional methods. These ... . Screening for cervical cancer with a Pap ...
... the University of North Carolina at Chapel Hill School of ... the collateral circulation the "back-up" blood vessels that can ... heart attack or stroke. The new knowledge could help ... drugs or procedures that can cause new collaterals to ...
... oil and methane leaked into the Gulf of Mexico suggests ... the source of the pollution. The research investigates five scenarios ... an estimated rate of flow from the Deepwater Horizon spill, ... April to mid July of this year. A ...
Cached Biology News:Electronic tracking system can improve follow-up after an abnormal Pap test 2Genetics underlie formation of body's back-up bypass vessels 2Deep plumes of oil could cause dead zones in the Gulf 2
... (GR) Competitor Assay Kits are ideal for ... The PolarScreen GR Competitor Assay Kits contain ... and one of the following proprietary fluorescent ... GS Red (red assay kit), or GS ...
McCoy's 5A Medium. Without Tryptose or Phosphate Broth. Contains Sodium Bicarbonate....
... pathway is the major proteolytic system ... where it catalyzes the selective degradation ... rapid elimination of proteins with abnormal ... 1996). The critical protease in this ...
... to RFC1 Immunogen Recombinant protein corresponding ... C expressed in E. coli. Reactivity / ... Not yet tested in other species. This antibody ... Background Information Replication factor C is a ...
Biology Products: